Previous 10 | Next 10 |
The following slide deck was published by Marinus Pharmaceuticals, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Marinus Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation
Truist analyst Joon Lee raised the price target on Marinus Pharmaceuticals (NASDAQ:MRNS +4.9%) to $50 from $35 and maintains a Buy rating on the shares. The analyst cites the company's Q4 results and additional updates on the planned launch of Ztalmy, stating that its annualized pricing of $1...
Marinus Pharmaceuticals, Inc. (MRNS) Q4 2021 Results Conference Call March 21, 2022 08:00 AM ET Company Participants Sasha Damouni - VP, IR and Corporate Communications Dr. Scott Braunstein - Chief Executive Officer Dr. Joe Hulihan - Chief Medical Officer Kimberly McCormick - Senior Vice Pres...
After a sharp rise following the U.S. approval of its seizure therapy Ztalmy last week, Radnor, Pennsylvania-based Marinus Pharmaceuticals (MRNS -11.7%) has recorded its biggest intra-day loss in nearly a month on Monday in reaction to its worse-than-expected Q4 2021 financials. After a ~1% Y...
Marinus Pharmaceuticals press release (NASDAQ:MRNS): Q4 GAAP EPS of -$0.77 misses by $0.02. Revenue of $1.52M (-1.3% Y/Y) misses by $1.98M. Shares -7.7% PM. “This year has already proven to be pivotal for Marinus following the FDA’s approval of ZTALMY®, the first and only t...
Received FDA approval of ZTALMY ® (ganaxolone) for the treatment of seizures associated with CDKL5 deficiency disorder; first approved treatment for this rare form of genetic epilepsy Awarded a Rare Pediatric Disease Priority Review Voucher by the FDA Eligible for an ...
Radnor, Pennsylvania-based Marinus Pharmaceuticals (NASDAQ:MRNS +26.8%) is trading sharply higher on Friday after the company announced the U.S. Food and Drug Administration (FDA) approved seizure treatment Ztalmy. The FDA has cleared Ztalmy, known as ganaxolone in generic terms, for the trea...
First and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder (CDD) in patients two years of age and older 1 ZTALMY significantly reduced major motor seizure frequency in CDD patients in the pivotal Marigold trial Rare Pediatric Disea...
Marinus Pharmaceuticals (NASDAQ:MRNS) is scheduled to announce Q4 earnings results on Monday, March 21st, before market open. The consensus EPS Estimate is -$0.74 (-34.5% Y/Y) and the consensus Revenue Estimate is $3.5M (+127.3% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward r...
AXU, MRNS, PDD For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Philadelphia, Pennsylvania--(Newsfile Corp. - July 15, 2024) - Attention Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS) Investors. A securities fraud class action lawsuit has been filed against Marinus on behalf of purchasers of Marinus securities between March 17, 20...
RAISE trial met its first co-primary endpoint demonstrating rapid cessation of status epilepticus in a highly refractory patient population The trial failed to achieve statistical significance on the second co-primary endpoint of the proportion of patients not progressing to IV anesthesia...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schal Law Firm PR Newswire LOS ANGELES , June 11, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing o...